Enavogliflozin
As of the edition of 20 October 2026, Enavogliflozin is a small molecule: in active development; acts on SLC5A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 33, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | P31639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 2 | 0 |
| Phase 1 | 15 | 6 | 1 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 8 | 2 | 3 | 0 |
| Phase 4 | 7 | 0 | 7 | 0 |
| All trials | 33 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daewoong | Lead sponsor of trials | 2017 to now |